Vmbook Online ordering

Intermune Inc

Intermune, Inc. was a biotechnology company focused on the research, development, and commercialization of therapies for fibrotic diseases. The company's lead product was Esbriet (pirfenidone), which was approved by the US Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive and fatal lung disease.

In terms of financials, Intermune, Inc. reported revenue of $203.6 million in 2015, representing a significant increase from the $73.4 million reported in 2014. The company's net loss for 2015 was $132.8 million, compared to a net loss of $214.3 million in 2014.

Intermune, Inc. had been experiencing rapid growth in recent years, driven by the success of Esbriet. In 2015, the company's revenue from Esbriet sales in the US was $135.3 million, up from $41.1 million in 2014. International sales of Esbriet also contributed significantly to the company's growth.

The company's earnings per share (EPS) had been negative due to the company's significant investment in research and development, as well as commercialization of Esbriet. However, the company had been making progress in reducing its net loss and moving towards profitability.

Intermune, Inc. was acquired by Roche Holding AG in October 2015 for approximately $8.3 billion. Following the acquisition, Intermune, Inc. ceased to exist as a separate publicly traded company and its stock was delisted from the NASDAQ stock exchange.